Many common human mesenchymal tumors, including gastrointestinal stromal tumor (GIST), rhabdomyosarcoma (RMS) and leiomyosarcoma (LMS), feature myogenic differentiation 1-3 . Here we report that intragenic deletion of the dystrophin-encoding and muscular dystrophy-associated DMD gene is a frequent mechanism by which myogenic tumors progress to high-grade, lethal sarcomas. Dystrophin is expressed in the non-neoplastic and benign counterparts of GIST, RMS and LMS tumors, and DMD deletions inactivate larger dystrophin isoforms, including 427-kDa dystrophin, while preserving the expression of an essential 71-kDa isoform. Dystrophin inhibits myogenic sarcoma cell migration, invasion, anchorage independence and invadopodia formation, and dystrophin inactivation was found in 96%, 100% and 62% of metastatic GIST, embryonal RMS and LMS samples, respectively. These findings validate dystrophin as a tumor suppressor and likely anti-metastatic factor, suggesting that therapies in development for muscular dystrophies may also have relevance in the treatment of cancer.
Human cancers featuring myogenic differentiation include LMS, RMS and GIST. GIST cells-although most closely resembling interstitial cells of Cajal (ICC)-often express myogenic differentiation markers, such as smooth muscle actin and calponin [4] [5] [6] [7] . Presumptive initiating mutations have been identified in these myogenic cancers, including germline TP53 mutations in individuals with LMS and RMS 8, 9 and gain-of-function KIT or PDGFRA mutations in individuals with GIST [10] [11] [12] . Somatic mutations contribute to tumorigenic progression in myogenic cancers-for example, through cell cycle dysregulation by CDKN2A or TP53 inactivation in GIST 13,14 -but few of these genetic progression mechanisms in myogenic cancers have been characterized.
To identify shared tumorigenic mechanisms in myogenic cancers, we performed genome-wide Affymetrix 250K SNP assays. These studies identified intragenic deletions in the Duchenne and Becker muscular dystrophy-associated gene DMD 15 in 25 of 40 (63%) high-grade myogenic cancers, including in 19 of 29 GIST, 3 of 4 RMS and 3 of 7 LMS tumors ( Fig. 1a) . Although DMD is an X-linked gene, the deletions were found in both male and female cases, including in 9 of 13 (69%) GISTs in men and in 10 of 16 (63%) GISTs in women (Supplementary Table 1 ). The DMD deletions identified in myogenic cancers were not found in companion non-neoplastic tissues, attesting to their somatic origin ( Fig. 1b) . DMD deletions, when present within a primary GIST, were perpetuated in subsequent metastatic lesions (Supplementary Fig. 1 ) and, when present in any GIST metastasis, were also found in other metastases from the same individual ( Supplementary Fig. 2) . DMD intragenic deletions were not detected in 58 non-myogenic sarcomas ( Supplementary  Table 2 ) and were observed only infrequently in 905 (4.3%) nonsarcoma human cancer cell lines in the Cancer Cell Line Encyclopedia program 16 (Supplementary Fig. 3) . These data show that the frequency of DMD deletions is higher in myogenic cancers than in non-myogenic cancers (P < 0.0001).
Whereas all DMD deletions in tumors from men were nullizygous, the deletions in tumors from women were either nullizygous (n = 9) or heterozygous (n = 4) ( Fig. 1c and Supplementary Table 1 ). FISH for DMD and the Xist marker of inactive X chromosomes 17 showed that, in tumors with heterozygous DMD deletions, the active X chromosome was targeted ( Fig. 1d) . Therefore, both nullizygous and heterozygous DMD deletions in females caused complete DMD inactivation.
Dystrophin is a tumor suppressor in human cancers with myogenic programs l e t t e r s DMD is the longest known human gene 15 , composed of 79 coding exons spanning 2.2 Mb of the genome, with various transcriptional start sites 18 . Multiplex ligation-dependent probe amplification (MLPA) copy number assessment for each of the DMD coding exons identified intragenic DMD deletions in 24 of 56 (43%) high-grade myogenic cancers ( Fig. 2,  Supplementary Fig. 4 and Supplementary  Table 3 ), all of which were predicted to abrogate expression of the largest (427-kDa) dystrophin isoform, encoded by DMD exons 1-79. In contrast, intragenic DMD deletions were not found in 20 benign counterparts of the Dp71 isoform in DMD-deleted RMS cells inhibited cell growth ( Supplementary Fig. 6 ), indicating that 71-kDa dystrophin has essential roles in myogenic cancer cells. These findings account for the obligate expression of 71-kDa dystrophin in myogenic cancers and explain why DMD genomic deletions rarely extend to the coding sequence for this isoform (Fig. 2) .
The biological function of dystrophin in myogenic cancers was evaluated by re-expressing it in DMD-inactivated GIST, RMS and LMS cells. Re-expression of 427-kDa dystrophin is challenging, owing to the large size of the cDNA construct. Therefore, we used a miniDMD construct lacking exons 17-48, which encode a spectrin-like domain 20 (Fig. 2) . This miniDMD construct is biologically relevant, insofar as its introduction restores crucial aspects of dystrophin function in gene therapy for individuals with muscular dystrophy 21 . Transfection of miniDMD into DMD-inactivated GIST, eRMS and LMS cells resulted in the expression of 240-kDa dystrophin at levels that were comparable to the physiological levels of 427-kDa dystrophin in low-risk F   118  31-1  116-5  116-4  114  109  121  120  72  84  83  80  64  59  58  57  54  52  48  47  44  40  39  62  61-10  56  55  51  50  45  43  31-2  42  34  33  28  16  15  36  35  31-1 of the GIST, RMS and LMS tumors (11 low-risk GIST, 2 RMS and 7 LMS tumors), despite high levels of dystrophin expression (Supplementary Table 3 ). The 427-kDa dystrophin isoform was expressed strongly in normal tissue and in benign counterparts for GIST, RMS and LMS tumors ( Fig. 3) but was undetectable or weakly expressed in 96% of metastatic GISTs (26 of 27), irrespective of whether they had KIT or PDGFRA mutations ( Fig. 3b and Supplementary Table 4 ). Similarly, expression of the 427-kDa isoform of dystrophin was undetectable or weak in 100% of metastatic embryonal RMS (eRMS) tumors (9 of 9) and in 62% of metastatic LMS tumors (8 of 13) ( Fig. 3c,d and Supplementary Table 4 ). Expression of the 427-kDa isoform of dystrophin was also downregulated in 75% of primary 'high-risk' GISTs (GISTs having histological criteria predictive of metastasis), consistent with the SNP evidence that DMD dysregulation is positively selected for in clinically aggressive primary tumors, even before metastasis ( Fig. 3b) .
Expression of 427-kDa dystrophin was not detected in 46 nonmyogenic sarcomas ( Supplementary Table 5 ). In contrast, expression of dystrophin isoform Dp71 (71 kDa), encoded by exons 63-79, was preserved in cancers with DMD deletion (Fig. 4) . The Dp71 isoform was also expressed in non-myogenic sarcomas ( Supplementary  Fig. 5 ), in keeping with reports that Dp71 expression is ubiquitous in non-neoplastic tissues other than skeletal muscle 19 . Knockdown npg l e t t e r s (indolent) GISTs, skeletal muscle and myometrium, respectively ( Supplementary Fig. 7) . Dystrophin re-expression inhibited the invasiveness and migration of GIST, eRMS and LMS cells but had no effect on the non-myogenic fibrosarcoma cell line HT-1080 ( Fig. 5a,b) , and re-expression reduced the number of viable eRMS and LMS cells but not the number of viable GIST, fibrosarcoma, Ewing's sarcoma or HEK 293 cells ( Supplementary Fig. 8 ). Dystrophin re-expression inhibited the anchorage-independent growth of DMDinactivated GIST, eRMS and LMS cells ( Fig. 6a ) but not that of comparator nonmyogenic fibrosarcoma or Ewing's sarcoma cells ( Fig. 6a and Supplementary Fig. 9 ). These studies support the hypothesis that DMD inactivation enhances metastatic potential selectively in cancers with myogenic programs.
Dystrophin provides a structural link between the actin-based cytoskeleton and the extracellular matrix 22, 23 , which is consistent with our evidence that dystrophin regulates invasion and migration in myogenic cancers. Metastases account for 90% of cancer-related deaths 24, 25 , and some invasive cancer cells feature invadopodia, which are actin-rich membrane protrusions that regulate metastatic behavior 26 . Restoration of DMD expression inhibited invadopodia formation in GIST and LMS cells ( Fig. 6b) , which is also consistent with dystrophin acting as an anti-metastatic factor. The genomic, clinicopathological and functional findings herein demonstrate that the tumor suppressor roles of dystrophin contribute to permissiveness for metastatic behavior in human cancers. The relevance of these findings is supported by reports of spontaneous RMS in Dmd-inactivated mdx mice [27] [28] [29] . Similarly, reports of RMS in individuals with Duchenne muscular dystrophy suggest that germline DMD inactivation may predispose to myogenic cancer 30, 31 GIST   GIST   GIST   GIST   GIST   GIST   GIST   GIST   GIST  3-30  35  36  38  39  40  44  46  49  51  52  54  55  56  60  63  64  80  83 npg l e t t e r s large gene, but, of the >40 human genes that are more than 1 Mb in genomic length, only DMD is known to have frequent deletions that seem subject to strong selective pressure in pre-metastatic GISTs. Several observations support DMD inactivation as a driver event in myogenic cancers.
(i) Frequent DMD deletions are not found in non-myogenic cancers (Supplementary Fig. 3) , most of which have more complex genomic landscapes than those in RMS and GIST 32 , indicating that clonal DMD deletions in advanced myogenic cancers are not attributable merely to cytogenomic complexity. (ii) DMD deletions are not found in benign precursors to GIST (Fig. 3b ) but rather are remarkably frequent, late events in GIST progression and are found in subclones that-on the basis of genomic evidence-overgrow subclones with wild-type DMD in the same tumors. (iii) Although DMD deletions represent a late event in tumorigenesis, the same DMD deletion found in one metastasis can be detected in all other metastases from a particular individual ( Supplementary Fig. 2) , consistent with a biological advantage for dystrophin inactivation. These genomic lines of evidence, coupled with the demonstration that DMD restoration only has an effect in myogenic cancers ( Figs. 5 and 6) , suggest that DMD mutations in myogenic cancers are classic tumor suppressor events. It is unclear whether the DMD mutation rate is particularly high in myogenic cancers, perhaps owing to mechanisms such as transcription-associated recombination 33 , but in any case the combined evidence summarized above suggests that DMD inactivation may be more than simply a passenger event in myogenic cancer. Previously, DMD deletions were identified in 5.5% of malignant melanomas 34 , but it is unknown whether these deletions had functional consequences. 
l e t t e r s
In clinically advanced myogenic cancers, we show that DMD inactivation abolishes expression of the 427-kDa isoform of dystrophin found in normal tissue and the benign counterparts of GIST, LMS and RMS tumors while preserving expression of the 71-kDa dystrophin protein, which appears to be an obligate factor in these cancers. Dystrophin interacts with a complex of sarcolemmal proteins and glycoproteins known as dystrophin-associated proteins 22 , and our demonstration of tumor suppressor roles for dystrophin anticipates that other proteins in this complex might regulate tumorigenic functions. In one example, the dystrophin-related protein utrophin is a potential tumor suppressor in non-myogenic malignancies 35 , and pharmacological induction of utrophin overexpression in mdx mice prevents the development of muscular dystrophy, suggesting that utrophin can compensate for dystrophin deficiency 36 . Other treatment options to correct dystrophin defects are undergoing evaluation in clinical trials for Duchenne muscular dystrophy [37] [38] [39] [40] , and these approaches warrant evaluation as potential therapeutic strategies in oncology. Identification of patients whose cancers have dystrophin defects might be expedited by immunohistochemical screening for loss of expression of 427-kDa dystrophin. Immunohistochemical assays show robust dystrophin expression in non-neoplastic myogenic cells (skeletal, cardiac and smooth muscle) and in leiomyomas (benign smooth muscle tumors) (Supplementary Fig. 10a,c) , whereas LMS tumors (malignant smooth muscle tumors) often feature complete loss of demonstrable dystrophin expression ( Supplementary Fig. 10b,c) . Therefore, dystrophin dysregulation warrants evaluation as a prognostic factor in myogenic cancers and as a potential point of therapeutic attack.
MeTHoDS
Methods and any associated references are available in the online version of the paper. SNP arrays. High-molecular-weight genomic DNA was isolated using the QIAamp DNA Mini kit (Qiagen) and analyzed by Affymetrix 250K SNP array. DNA was digested with Nsp1, and linkers were ligated to the restriction fragments to permit PCR amplification. PCR products were purified and fragmented by treatment with DNase I, and fragments were then labeled and hybridized to microarray chips. The positions and intensities of fluorescence emissions were analyzed using dChip software. Array intensity values were normalized to the value for the array with median intensity. Median smoothing was used to infer copy number. Multiplex ligation-dependent probe amplification. The MLPA procedure and capillary electrophoresis were performed using SALSA MLPA kits P034-A2 and P035-A2 from MRC-Holland. The combined P034 and P035 kits contain probes for each of the 79 DMD coding exons and for the alternative exon 1, Dp427c. MLPA reactions were conducted using a G-Storm GS1 thermal cycler (Gene Technologies) with fragment analysis by ABI-3130xl Genetic Analyzer and GeneMapper software (Applied Biosystems). Raw data were collected as peak heights, as a measure of peak intensity, for each of the probes.
Purification of mouse interstitial cells of Cajal. Mouse ICCs (~500,000) were isolated as KIT + CD44 + CD34cells from the hematopoietic markernegative (CD45 -F4/80 -CD11B -) fraction of the gastric tunica muscularis of 7-to 15-d-old BALB/c mice (males and females; n = 52 in 5 cohorts) as described previously 41, 42 . All protocols involving mice were approved by the Mayo Clinic Institutional Animal Care and Use Committee. The fidelity of ICC sorting was validated by demonstrating a >2.5-fold increase in KIT protein expression in sorted cells compared to unsorted cells and by lack of expression of the smooth muscle marker MYH11 and the pan-neural marker PGP 9.5 by protein blotting. Primary antibodies were to KIT (R&D Systems, AF1356, 1:1,000 dilution), MYH11 (Biomedical Technologies, BT-562, 1:10,000 dilution), PGP 9.5 (UltraClone, RA95101, 1:15,000 dilution) and GAPDH (Sigma, G9545, 1:40,000 dilution and Imgenex, IMG-3073, 1:10,000 dilution). Cell lines. GIST-T1 cells were generously provided by T. Taguchi 43 . HT-1080 and HEK 293 cells were obtained from the American Type Culture Collection. All other cell lines were developed in the laboratory of J.A.F. at Brigham and Women's Hospital. GIST-T1 and GIST430 cells were established from metastatic GISTs with deletions of DMD exon 1 and exons 1-9, respectively. RMS176 cells were established from a metastatic eRMS sample with DMD deletions of exons 1-7 and exons 21-44, respectively. LMS04 cells were established from a metastatic LMS sample without apparent DMD deletion but with complete loss of expression of 427-kDa dystrophin. HT-1080 fibrosarcoma 44 and EWS502 Ewing's sarcoma cells were non-myogenic controls with wild-type DMD. Cells were tested for mycoplasma contamination using the MycoAlert Mycoplasma Detection kit (LT07-218, Lonza).
Stable transfections.
GIST-T1, GIST430, RMS176, LMS04 and EWS502 cell monolayers were disaggregated with trypsin and resuspended in Amaxa Nucleofector solution V (Amaxa Biosystems) at a concentration of 1 × 10 6 cells per 100 µl. Nucleofection was performed using program T-030 on a Nucleofector II machine (Amaxa Biosystems). One microgram of pCR3.1-EGFP or pCR3.1-miniDMD plasmid was used for electroporation. Transfected cells were selected with G418 for 5 d before analyses.
Knockdown with Dp71 siRNA. Dp71-specific small interfering RNA (siRNA), targeting the unique region in exon 1 of Dp71, was obtained from Invitrogen (sequence provided in Supplementary Table 6 ). Control siRNA was obtained from Invitrogen (Stealth RNAi siRNA Negative Control Medium GC Duplex, 12935-300). siRNA was delivered to RMS176 and RMS843 cells by nucleofection (Amaxa Biosystems) as described previously 45 .
Cell viability assays. Viability studies were performed using the CellTiter-Glo luminescence assay (Promega). Cells were plated at a density of 2,000 cells per well in a 96-well flat-bottomed plate (Falcon). Luminescence was analyzed using a Veritas microplate luminometer (Turner Biosystems).
Soft agar assays. Cells were plated in 35-mm dishes after stable transfection with EGFP or miniDMD. Cells were incubated for 3-4 weeks and then stained with 1 ml of 1 mg/ml methylthiazol tetrazolium (MTT) for 3 h. Colonies were counted manually. All experiments were performed in triplicate.
Quantitative cell invasion and migration assays. Serum-free medium (0.3 ml) containing 0.3 × 10 5 GIST-T1, GIST430, RMS176 or LMS04 cells was plated for invasion assays in BD BioCoat Matrigel invasion chambers (BD Biosciences, 354480) and for migration assays in BD BioCoat 8.0-µm PET membrane 24-well cell culture inserts (BD Biosciences, 354578). Cells in each well were fed with 0.5 ml of RPMI-1640 (Invitrogen) containing 15% FBS and were incubated in a humidified incubator at 37 °C and 5% CO 2 for 144 h (GIST-T1), 72 h (GIST430) or 24 h (RMS176, LMS04 and HT-1080). Medium from the inside of the insert was aspirated, and the interiors of the inserts were gently swabbed to remove non-invasive or non-migratory cells. Inserts were transferred to new wells containing 400 µl of Cell Stain Solution (Cell Biolabs) and incubated for 10 min at room temperature. They were then rinsed two times in a beaker of water and were air dried and transferred to new wells containing 200 µl of Extraction Solution (Cell Biolabs). Cells were quantified at an OD of 560 nm in a microplate reader.
Radius two-dimensional cell migration assays. The impact of dystrophin restoration on cell migration was determined using a two-dimensional gap closure radius 24-well migration assay, according to the manufacturer's instructions (Cell Biolabs).
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